FineHeart
A Healthier Life With Every Beat

Press Release

FineHeart Selected as One of The Top Ten Cardiac Abstracts to present at the 66th Annual ASAIO Conference

American Society for Artificial Internal Organs
June 10 -12 Washington, DC

Bordeaux, France (June 8, 2021) – FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER®, an Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced that it has been chosen to present at the 66th annual ASAIO conference, which will take place on June 10 -12 at the Hilton DC Hotel in Washington, DC.

Laurent Barandon, MD, PhD, Cardiac Surgeon at the University of Bordeaux, FR and Stephane Garrigue, MD, PhD, Chief Scientific Officer of FineHeart will present *In-vivo Assessment of A Novel Ventricular Systole-synchronized, Intraventricular Propelling, Left Ventricular Assist Device For Advanced Heart Failure,* selected as one of the top ten cardiac abstracts.
The Presentation will take place, Thursday June 10, 2021, at 8:15 am EST (14:15 CET).
The abstract will show the lastest preclinical results in terms of performance and mid-term safety.

ASAIO's annual conference globally and collaboratively promotes the development of innovative medical device technology at the crossroads of science, engineering, and medicine. Dedicated sessions are devoted to pediatric and adult mechanical circulatory support, respiratory assist, and VAD coordinator training.

About the ICOMS FLOWMAKER®

The ICOMS FLOWMAKER® is the first fully intraventricular, wireless flow accelerator that provides physiological support synchronized with the heart's natural contractions. It respects the natural blood flow and does not require aortic bypass surgery. It is the first miniaturized device - barely 10 cm in size - that is adjustable to patients' needs, like a pacemaker to treat patients with varying degrees of severity. It has no external driveline as it is recharged via a wireless transcutaneous energy transfer system (TET). The device is implanted using a minimally invasive beating-heart procedure, commonly performed by cardiac surgeons, and lasts on average 90 minutes.

FineHeart demonstrates that the protocol for implanting and removing the ICOMS FLOWMAKER® resolves the severe complications associated with implantation of left ventricle assist device (LVAD) surgery, which deteriorates the fragile cardiovascular condition of the patients treated. Today, within two years of the implantation of a classic LVAD, 80% of patients develop a severe complication that makes them dependent on their assistance device.

About Heart Failure

Heart failure (HF) is the second leading cause of death in the United States and Europe and has become a global pandemic affecting 26 million people worldwide, with a steadily rising incidence (over one million new cases in G8 countries). This degenerative disease is associated with a reduced quality of life, frequent, costly hospitalizations, and early mortality. Cases of severe HF require a device to improve the pumping capacity of the left ventricle. Despite the pressing need, current LVADs are bulky, which causes significant myocardial damage. They are associated with a risk of infection, bleeding, and thrombosis, which is why they are almost exclusively implanted in very severe patients with short life expectancy. In the event of a sudden attack (cardiogenic shock), it is often necessary to wait before deciding whether to implant an LVAD and force physicians to resort to temporary circulatory assist solutions. These less invasive aids are limited in time (30 days maximum) and require the patient is bedridden a large part of the time. The prospect of a single device, such as the ICOMS FLOWMAKER®, that is capable of providing both temporary support (with no time limit and preserving the patient's mobility) and permanent support if the patient does not recover sufficiently from the shock, constitutes a paradigm shift in the way severe Heart Failure patients will be treated.

About FineHeart - www.fineheart.fr

FineHeart is a French medical device company headquartered in Bordeaux. Its patented ICOMS innovation holds the potential to treat 200,000 severe heart failure patients annually, with FineHeart initially targeting the 50,000 patients who are eligible for hemodynamic support but today are not treated by current LVADs; a $5B unmet market need.

FineHeart was founded in 2010 by a team of internationally renowned cardiac surgeons and cardiologists, led by Stephane Garrigue, MD, PhD, CSO, Philippe Ritter, MD, MS, co-inventor of cardiac resynchronization therapy (CRT), and FineHeart CEO, Arnaud Mascarell. The company benefits today from 17 patent families.

FineHeart is supported by major U.S. venture capital firms specializing in the cardiovascular space, prime French investors, the European Union, and Region Nouvelle Aquitaine and Region Centre. It has been recognized by FierceMedTech as one of its "Fierce 15," designating it as one of the most promising private MedTech companies in the industry.

Contacts

US and International
Dana Summers
Penman PR for FineHeart
dana@penmanpr.com

Europe
NewCap Media Relations
Annie-Florence Loyer
afloyer@newcap.fr
+33 (6) 88 20 35 59

Agile Capital Markets
Sophie Baratte
Sophie.baratte@agilecapitalmarkets.com

FineHeart Communications
James Palmer
j.palmer@orpheonfinance.com
+33 (0) 7 60 92 77 72